Insmed, Inc. (INSM)
114.40
+5.64
(+5.19%)
USD |
NASDAQ |
Nov 06, 16:00
114.48
+0.08
(+0.07%)
After-Hours: 20:00
Insmed Cash from Investing (Quarterly) : -135.65M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -135.65M |
| June 30, 2026 | 24.51M |
| March 31, 2026 | 265.52M |
| December 31, 2025 | 389.41M |
| September 30, 2025 | -762.23M |
| June 30, 2025 | 227.84M |
| March 31, 2025 | 80.41M |
| December 31, 2024 | 131.76M |
| September 30, 2024 | -1.003B |
| June 30, 2024 | -6.783M |
| March 31, 2024 | 295.32M |
| December 31, 2023 | 1.803M |
| September 30, 2023 | 7.147M |
| June 30, 2023 | -274.16M |
| March 31, 2023 | 41.60M |
| December 31, 2022 | 20.31M |
| September 30, 2022 | 49.42M |
| June 30, 2022 | -2.904M |
| March 31, 2022 | -101.41M |
| December 31, 2021 | -51.22M |
| September 30, 2021 | -8.401M |
| June 30, 2021 | -3.485M |
| March 31, 2021 | -1.181M |
| December 31, 2020 | -1.515M |
| September 30, 2020 | -0.747M |
| Date | Value |
|---|---|
| June 30, 2020 | -1.881M |
| March 31, 2020 | -2.679M |
| December 31, 2019 | -13.04M |
| September 30, 2019 | -14.59M |
| June 30, 2019 | -10.61M |
| March 31, 2019 | -4.028M |
| December 31, 2018 | -4.751M |
| September 30, 2018 | -1.851M |
| June 30, 2018 | -2.847M |
| March 31, 2018 | -5.365M |
| December 31, 2017 | -1.70M |
| September 30, 2017 | -0.447M |
| June 30, 2017 | -0.437M |
| March 31, 2017 | -0.417M |
| December 31, 2016 | -0.772M |
| September 30, 2016 | -1.30M |
| June 30, 2016 | -1.54M |
| March 31, 2016 | -0.588M |
| December 31, 2015 | -0.407M |
| September 30, 2015 | -0.853M |
| June 30, 2015 | -0.93M |
| March 31, 2015 | -1.264M |
| December 31, 2014 | -1.527M |
| September 30, 2014 | -2.919M |
| June 30, 2014 | -0.564M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | -311.74M |
| Gilead Sciences, Inc. | -244.00M |
| Incyte Corp. | -44.34M |
| Vertex Pharmaceuticals, Inc. | -6.101B |
| Regeneron Pharmaceuticals, Inc. | -288.10M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -36.46M |
| Cash from Financing (Quarterly) | 23.64M |
| Free Cash Flow | -657.58M |
| Free Cash Flow Per Share (Quarterly) | -0.1924 |
| Free Cash Flow to Equity (Quarterly) | -44.57M |
| Free Cash Flow to Firm (Quarterly) | -21.12M |
| Free Cash Flow Yield | -2.66% |